IL248530D0 - Biomarkers and methods of treatment - Google Patents

Biomarkers and methods of treatment

Info

Publication number
IL248530D0
IL248530D0 IL248530A IL24853016A IL248530D0 IL 248530 D0 IL248530 D0 IL 248530D0 IL 248530 A IL248530 A IL 248530A IL 24853016 A IL24853016 A IL 24853016A IL 248530 D0 IL248530 D0 IL 248530D0
Authority
IL
Israel
Prior art keywords
biomarkers
treatment
methods
Prior art date
Application number
IL248530A
Other languages
Hebrew (he)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US37891110P priority Critical
Priority to US38992210P priority
Priority to US39099510P priority
Priority to US42070310P priority
Priority to US201161487527P priority
Priority to US201161492338P priority
Priority to US201161503489P priority
Priority to PCT/US2011/050069 priority patent/WO2012031027A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL248530D0 publication Critical patent/IL248530D0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00Subject matter not provided for in other groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis
IL248530A 2010-08-31 2016-10-26 Biomarkers and methods of treatment IL248530D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US37891110P true 2010-08-31 2010-08-31
US38992210P true 2010-10-05 2010-10-05
US39099510P true 2010-10-07 2010-10-07
US42070310P true 2010-12-07 2010-12-07
US201161487527P true 2011-05-18 2011-05-18
US201161492338P true 2011-06-01 2011-06-01
US201161503489P true 2011-06-30 2011-06-30
PCT/US2011/050069 WO2012031027A1 (en) 2010-08-31 2011-08-31 Biomarkers and methods of treatment

Publications (1)

Publication Number Publication Date
IL248530D0 true IL248530D0 (en) 2016-12-29

Family

ID=44583514

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248530A IL248530D0 (en) 2010-08-31 2016-10-26 Biomarkers and methods of treatment

Country Status (15)

Country Link
US (2) US20120089541A1 (en)
EP (2) EP3264089A1 (en)
JP (2) JP2013537966A (en)
KR (1) KR20130103734A (en)
CN (1) CN103221825A (en)
AU (1) AU2011295919A1 (en)
BR (1) BR112013004673A8 (en)
CA (1) CA2808236A1 (en)
DK (1) DK2612151T3 (en)
ES (1) ES2641916T3 (en)
IL (1) IL248530D0 (en)
MX (1) MX2013002084A (en)
RU (1) RU2013114360A (en)
SG (2) SG10201408229WA (en)
WO (1) WO2012031027A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906099A2 (en) * 2008-03-06 2015-07-21 Genentech Inc "cancer treatment method in an individual"
TWI600760B (en) 2009-11-05 2017-10-01 建南德克公司 Methods and composition for secretion of heterologous polypeptides
AR086823A1 (en) 2011-06-30 2014-01-22 Genentech Inc Formulations of anti-c-met, methods
KR20140064971A (en) 2011-09-19 2014-05-28 제넨테크, 인크. Combination treatments comprising c-met antagonists and b-raf antagonists
EA201490676A1 (en) * 2011-09-22 2015-02-27 Экселиксис, Инк. Method of treating osteoporosis
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
KR101938699B1 (en) * 2012-07-23 2019-01-16 삼성전자주식회사 Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies
KR101938698B1 (en) 2012-07-23 2019-01-16 삼성전자주식회사 Use of Cbl as a biomarker for identifying a subject for application of anti c-Met antibodies
CN104487087A (en) * 2012-07-27 2015-04-01 基因泰克公司 Methods of treating FGFR3 related conditions
AU2013307383A1 (en) * 2012-08-27 2015-03-26 Cemm - Forschungszentrum Fur Molekulare Medizin Gmbh Aminoheteroaryl compounds as MTH1 inhibitors
WO2014066860A2 (en) * 2012-10-25 2014-05-01 Cedars-Sinai Medical Center Methods of prognosticating and treating cancer
KR20140093347A (en) * 2013-01-15 2014-07-28 삼성전자주식회사 Genes inducing agonistic effects by anti-c-Met antibody treatment and drug method using thereof
MX2015011833A (en) * 2013-03-07 2016-06-02 Barmarsa Res Llc Kits and methods for the treatment of cancer using gliadin peptides.
WO2014150819A2 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treatment
WO2015010596A1 (en) * 2013-07-22 2015-01-29 北京盛诺基医药科技有限公司 Prognosis diagnosis method of breast cancer
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
EP2891884B1 (en) 2014-01-07 2017-10-25 Samsung Electronics Co., Ltd IL-8 for predicting or monitoring efficacy of c-MET inhibitor
CN106103730A (en) 2014-03-14 2016-11-09 豪夫迈·罗氏有限公司 Method and composition for secretion of heterologous polypeptides
JP2017516458A (en) * 2014-03-24 2017-06-22 ジェネンテック, インコーポレイテッド Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
US20160327559A1 (en) * 2014-04-24 2016-11-10 Fundació Institut Mar D'investigacions Mèdiques (Imim) Hepatocyte growth factor as marker of prognosis in small cell lung cancer (sclc)
KR20160024639A (en) 2014-08-26 2016-03-07 삼성전자주식회사 PDGF as a biomarker for predicting resistance or effect of c-Met targeting drugs
JP2016155776A (en) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 Antitumor effect enhancer and antitumor agent
CN105087775A (en) * 2015-07-24 2015-11-25 北京莱尔生物医药科技有限公司 Method and related kit for detecting c-MET/CEP7 gene status based on rare cells
EP3352859A4 (en) * 2015-09-24 2019-04-10 Expression Pathology, Inc. Quantifying met protein for cancer treatment
CN107561625A (en) * 2016-06-30 2018-01-09 扬升照明股份有限公司 Light source module group and light guide plate
CN109963562A (en) 2016-11-16 2019-07-02 伊莱利利公司 For skip mutation with exons 14 or exons 14 skip phenotype cancer combination treatment
KR20190135028A (en) 2017-03-30 2019-12-05 메르크 파텐트 게엠베하 Combination of anti-PD-L1 antibodies and DNA-PK inhibitors for the treatment of cancer
WO2019211489A1 (en) 2018-05-04 2019-11-07 Merck Patent Gmbh COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
WO2020064971A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific and oligo-specific, mono- and oligovalent anti-body constructs, their production and use
DE69025946T2 (en) 1989-09-08 1996-10-17 Univ Johns Hopkins Modifications of the structure of the egf receptor gene in human glioma
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU685752B2 (en) 1992-06-30 1998-01-29 Arqule, Inc. Aminimide-containing molecules and materials as molecular recognition agents
DE69329503T2 (en) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DK0659439T3 (en) 1993-12-24 2002-01-14 Merck Patent Gmbh immunoconjugates
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248D0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric antibody and humanized against the receptor for epidermal growth factor diagnostic and therapeutic use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AT212993T (en) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine and method for the production thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6344459B1 (en) 1996-04-12 2002-02-05 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AT227283T (en) 1996-07-13 2002-11-15 Glaxo Group Ltd Condensed heterocyclic compounds as protein kinase inhibitors
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag Pirazola derivative fused and the manufacturing process
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (en) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Use of quinazoline compounds for the treatment of renal polychystosis disease.
DE69830315T2 (en) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylated glycoprotein containing compositions and method for the production thereof
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2001521909A (en) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド Methods and compositions comprising glycoprotein glycoforms
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AT531812T (en) 1997-12-05 2011-11-15 Scripps Research Inst Humanization of nager antibodies
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
KR20010080491A (en) 1998-11-19 2001-08-22 로즈 암스트롱, 크리스틴 에이. 트러트웨인 N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an Irreversible Inhibitor of Tyrosine Kinases
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL144056D0 (en) 1999-01-15 2002-04-21 Genentech Inc Polypeptide variants with altered effector function
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk Process for producing polypeptide
CZ301689B6 (en) 1999-11-05 2010-05-26 Astrazeneca Ab Quinazoline derivative and pharmaceutical composition in which the derivative is comprised
JP2003516755A (en) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2637801T3 (en) 2000-04-11 2017-10-17 Genentech, Inc. multivalent antibodies and uses thereof
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
AU2001294198C1 (en) 2000-10-06 2019-04-04 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP2005524379A (en) 2001-08-03 2005-08-18 グリカート バイオテクノロジー アクチェンゲゼルシャフト Antibody glycosylation variants with enhanced antibody-dependent cytotoxicity
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
MXPA04003798A (en) 2001-10-25 2004-07-30 Genentech Inc Glycoprotein compositions.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
JPWO2003084569A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Antibody composition-containing medicine
BR0309145A (en) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Cells from which the genome is modified
CA2481656A1 (en) 2002-04-09 2003-10-16 Yutaka Kanda Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004087207A2 (en) 2003-03-27 2004-10-14 Georgetown University Method for inducing apoptosis and aneuploidy regression in cancer cells
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc Antibodies directed to c-MET
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
CN102373214B (en) 2003-11-05 2014-07-09 罗氏格黎卡特股份公司 Antigen binding molecules with increased fc receptor binding affinity and effector function
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
AT554107T (en) 2003-12-19 2012-05-15 Genentech Inc Therapeutically suitable monovalent antibody fragments
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN101035808B (en) 2004-08-05 2012-10-31 健泰科生物技术公司 Humanized anti-CMET antagonists
ES2669510T3 (en) 2004-09-23 2018-05-28 Genentech, Inc. Antibodies and conjugates engineered with cysteine
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2004693B1 (en) 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
PT2027156E (en) 2006-06-02 2011-04-18 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (en) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 -/ anti-hgf/sf humanized antibody and method for the preparation thereof
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009054939A2 (en) * 2007-10-19 2009-04-30 Cell Signaling Technology, Inc. Cancer classification and methods of use
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
BRPI0906099A2 (en) * 2008-03-06 2015-07-21 Genentech Inc "cancer treatment method in an individual"
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
WO2010045345A2 (en) 2008-10-17 2010-04-22 Genentech, Inc. Treatment method
EP2722400A3 (en) * 2008-10-29 2014-07-09 William Beaumont Hospital Methods of using biomarkers
PA8849001A1 (en) 2008-11-21 2010-06-28 Lilly Co Eli Antibodies c-met
SG175078A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (en) 2009-10-30 2016-11-01 삼성전자 주식회사 c-Met specific antibodies and uses thereof
KR101748707B1 (en) 2009-11-27 2017-06-20 삼성전자주식회사 c-Met specific antibodies and diagnosis kit for cancer using thereof

Also Published As

Publication number Publication date
EP2612151A1 (en) 2013-07-10
CN103221825A (en) 2013-07-24
BR112013004673A2 (en) 2016-08-02
JP2013537966A (en) 2013-10-07
SG10201408229WA (en) 2015-02-27
US20120089541A1 (en) 2012-04-12
EP2612151B1 (en) 2017-08-09
SG187886A1 (en) 2013-04-30
ES2641916T3 (en) 2017-11-14
MX2013002084A (en) 2013-05-09
CA2808236A1 (en) 2012-03-08
EP3264089A1 (en) 2018-01-03
RU2013114360A (en) 2014-10-10
BR112013004673A8 (en) 2018-01-02
DK2612151T3 (en) 2017-10-02
KR20130103734A (en) 2013-09-24
JP2016105096A (en) 2016-06-09
US20140037625A1 (en) 2014-02-06
AU2011295919A1 (en) 2013-03-07
WO2012031027A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
HRP20171189T1 (en) Bisaryl-bonded aryltriazolones and use thereof
HRP20172004T1 (en) Anti-fap antibodies and methods of use
IL261768D0 (en) Devices and methods for the treatment of tissue
HRP20160609T1 (en) Methods of treatment of hepatocellular carcinoma
HK1194933A1 (en) Protective case and methods of making
ZA201400141B (en) Keto-isovalerate decarboxylase enzymes and methods of use thereof
IL233096D0 (en) Ratio based biomarkers and methods of use thereof
IL225867D0 (en) Novel coelenterazine substrates and methods of use
IL227440A (en) Ballstent device and methods of use
HK1179608A1 (en) Forms of rifaximin and uses thereof
ZA201208815B (en) Methods of treating bladder cancer
EP2791333A4 (en) Opsin polypeptides and methods of use thereof
HK1180326A1 (en) Pyridone and aza-pyridone compounds and methods of use
EP2777371A4 (en) Protective cases and methods of making
EP2723384A4 (en) Treatment of proteinopathies
ZA201304153B (en) Anti-pcsk9 antibodies and methods of use
IL226401D0 (en) Methods of treating fgf21-associated disorders
IL247595D0 (en) Novel modulators and methods of use
ZA201209484B (en) Skin antiaging treatment
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
EP2661264A4 (en) Melanin modification compositions and methods of use
IL223189D0 (en) Methods of treatment of pancreatic cancer
ZA201207543B (en) Redox-flow battery and method of operating thereof
IL220939D0 (en) Compounds and methods
HRP20171352T1 (en) Wnt antagonists and methods of treatment